TY - JOUR T1 - Highly Accurate and Reproducible Diagnosis of Peanut Allergy Using Epitope Mapping JF - medRxiv DO - 10.1101/2020.06.19.20136002 SP - 2020.06.19.20136002 AU - Paul Kearney AU - Robert Getts AU - Clive Hayward AU - David Luta AU - Alex Porter AU - Marc Witmer AU - George du Toit AU - Gideon Lack AU - R. Sharon Chinthrajah AU - Stephen J Galli AU - Kari Nadeau AU - Galina Grishina AU - Mayte Suárez-Fariñas AU - Maria Suprun AU - Hugh A Sampson Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/20/2020.06.19.20136002.abstract N2 - Background Misdiagnosis of peanut allergy is a significant clinical challenge. Here, a novel diagnostic blood-based test using a Bead-Based Epitope Assay (“peanut BBEA”) has been developed on the LEAP cohort and then independently validated on the CoFAR2 and POISED cohorts.Methods Development of the peanut BBEA followed the National Academy of Medicine’s established guidelines with discovery performed on 133 subjects from the non-interventional arm of the LEAP trial and an independent validation performed on 81 subjects from the CoFAR2 study and 84 subjects from the POISED study. All subject samples were analyzed using the BBEA methodology. The peanut BBEA test measures levels of two Ara h 2 epitopes and compares their combination to a pre=specified threshold. If the combination of the two epitope levels is at or below the threshold, then the subject is ruled “Not Allergic”, otherwise the subject is ruled “Allergic”.All allergic diagnoses were OFC confirmed and subjects’ ages were 7-55 years.Results In validation on the CoFAR2 and POISED cohorts, the peanut BBEA test had a combined sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, negative likelihood ratio and accuracy of 91%, 95%, 95%, 91%, 18.2, 0.09 and 93%, respectively.Conclusion The peanut BBEA test performance in validation demonstrated overall high accuracy and compared very favorably with existing diagnostic tests for peanut allergy including skin prick testing, peanut sIgE and peanut component testing.Competing Interest StatementAuthors have the following declarations. PK, RG, CH, DL, AP and MW have received compensation from AllerGenis. SC and HS are advisors to AllerGenis.Funding StatementNo external funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Stanford IRB, Stanford University, 3000 ElCamino Real, Five Palo Alto Square, 4th Floor, Palo Alto, CA.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting the manuscript is available by contacting paul.kearney{at}allergenis.com. ER -